The Study Of Lysine Crotonylation As A Tumor Biomarker And Its Correlation With Pathologic Grades And Clinical Stages

Malignant tumor is one of the main causes of death in the world.With aging,morbidity and mortality are gradually increasing.Surgery,radiotherapy,chemotherapy and drugs targeting partly arrested the harm of the malignant tumor.High sensitivity and specificity marker is still needed for tumor diagnosis and prognosis evaluation.Histone crotonylation is a dynamic process regulated by histone crotonyltransferases(HCTs)and histone decrotonylases(HDCRs).p300/CBP is capable of enhancing transcriptional activation through its ability to catalyze histone crotonylation,the function is stronger compared to catalyze histone acetylation.We investigated the levels of lysine crotonylation and Histone H4 acetylation in prostate cancer,bladder cancer,renal cell carcinoma,lung cancer,liver cancer,colon cancer and breast cancer vs normal tissue using immunohistochemistry or western blot.After owning histochemistry score and operating statistic analysis,we found a substantial decreased level of lysine crotonylation in all cancers(P < 0.05),and a positive correlation with grades in prostate cancer and colon cancer.There was no significant difference in Histone H4 acetylation in prostate cancer and breast cancer vs normal tissue,in which lysine crotonylation was a better biomarker.In other cancers,we also found a decreased level of Histone H4 acetylation.We believe that crotonylation is a potential biomarker for the diagnosis,progression,and prognosis of cancer.